Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24868490 | 0.81 | BUB1 (0.33) | BUB1SPHK1DDB1CRBN | |
| SCHEMBL24868487 | 0.77 | GPR119 (0.36) | KDM1A | |
| SCHEMBL24868488 | 0.75 | BUB1 (0.36) | BUB1SPHK1DDB1CRBNCTSK | |
| SCHEMBL24868485 | 0.71 | CCR2 (0.32) | KDM1A | |
| SCHEMBL24248752 | 0.70 | BUB1 (0.34) | BUB1KDM1ADDB1CRBN | |
| SCHEMBL28658311 | 0.70 | BUB1 (0.34) | BUB1KDM1ADDB1CRBN | |
| SCHEMBL28658312 | 0.70 | BUB1 (0.34) | BUB1KDM1ADDB1CRBN | |
| SCHEMBL25092592 | 0.70 | BUB1 (0.34) | BUB1KDM1ADDB1CRBN | |
| SCHEMBL30299945 | 0.70 | BUB1 (0.34) | BUB1KDM1ADDB1CRBN | |
| SCHEMBL27228232 | 0.70 | BUB1 (0.42) | BUB1DDB1CRBNCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008867-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008867-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | BUB1 3104/4885SPHK1 1127/4885KDM1A 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.